- Home
- UP vs AUPH Comparison
UP vs AUPH Comparison
Compare UP & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UP
- AUPH
- Stock Information
- Founded
- UP 2013
- AUPH 1993
- Country
- UP United States
- AUPH Canada
- Employees
- UP N/A
- AUPH N/A
- Industry
- UP Aerospace
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- UP Consumer Discretionary
- AUPH Health Care
- Exchange
- UP Nasdaq
- AUPH Nasdaq
- Market Cap
- UP 1.4B
- AUPH 1.6B
- IPO Year
- UP N/A
- AUPH 1999
- Fundamental
- Price
- UP $1.30
- AUPH $13.17
- Analyst Decision
- UP
- AUPH Strong Buy
- Analyst Count
- UP 0
- AUPH 2
- Target Price
- UP N/A
- AUPH $13.00
- AVG Volume (30 Days)
- UP 5.6M
- AUPH 1.3M
- Earning Date
- UP 11-05-2025
- AUPH 11-04-2025
- Dividend Yield
- UP N/A
- AUPH N/A
- EPS Growth
- UP N/A
- AUPH N/A
- EPS
- UP N/A
- AUPH 0.42
- Revenue
- UP $765,885,000.00
- AUPH $260,111,000.00
- Revenue This Year
- UP $174.46
- AUPH $17.33
- Revenue Next Year
- UP N/A
- AUPH $14.31
- P/E Ratio
- UP N/A
- AUPH $31.33
- Revenue Growth
- UP N/A
- AUPH 25.59
- 52 Week Low
- UP $0.74
- AUPH $6.55
- 52 Week High
- UP $3.50
- AUPH $13.54
- Technical
- Relative Strength Index (RSI)
- UP 35.12
- AUPH 65.73
- Support Level
- UP $1.41
- AUPH $11.96
- Resistance Level
- UP $1.70
- AUPH $12.70
- Average True Range (ATR)
- UP 0.12
- AUPH 0.47
- MACD
- UP -0.02
- AUPH 0.17
- Stochastic Oscillator
- UP 4.76
- AUPH 85.96
About UP Wheels Up Experience Inc.
Wheels Up Experience Inc is a provider of on-demand private aviation in the United States. It is pioneering data and technology-driven solutions that connect consumers to safety-vetted and verified private aircraft. It connects private flyers to aircraft, and one another, through an open platform that enables life's most important experiences. Its offering is delivered through a mix of programmatic and charter options that strategically utilize its owned and leased aircraft fleet and an "asset-light" charter model to deliver a greater range of global travel alternatives. The company operates in a single operating and reportable segment, private aviation services. Geographically the company generates the majority of its revenue from the United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.